Cheng Hu
Co-Founder & Chief Executive Officer Technetium Therapeutics
Cheng Hu is Co-Founder and Chief Executive Officer of Technetium Therapeutics, where he is advancing AI-driven drug discovery. With more than two decades of medicinal chemistry and biotechnology experience, he has held leadership positions at Atomwise, Denali Therapeutics, Nurix, Novartis, and ChemoCentryx. His work has helped pioneer the integration of artificial intelligence into therapeutic discovery across oncology, immunology, inflammation, and targeted protein degradation.
Seminars
Wednesday 27th January 2027
Panel Discussion: Can AI and Computational Methods Crack the Molecular Glue Code? Turning Predictions into Validated Hits
9:30 am
- How can AI-powered and computational approaches be used to identify gluable surfaces, target-ligase pairings, and novel molecular glue opportunities, while integrating target selection with the practical challenge of finding tractable gluable interfaces?
- How can the molecular glue field overcome limited datasets to improve model training, predictive accuracy, and biological relevance, enabling more reliable AI-driven discovery workflows?
- How can computational predictions be most effectively combined with experimental screening, structural biology, and validation strategies to accelerate hit identification and optimize molecular glue potency and selectivity?
